Journal
BIOMEDICINES
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines11030830
Keywords
Muscular Dystrophy (MD); dystrophin expressing chimeric cells; DEC; systemic-intraosseous administration; muscular dystrophy therapeutics
Ask authors/readers for more resources
Despite the cloning of Dystrophin cDNA 35 years ago, there is still no effective treatment for patients with Duchenne Muscular Dystrophy (DMD) caused by a mutation in this gene. However, many novel therapies are currently in development and some have progressed to clinical trials.
Despite the full cloning of the Dystrophin cDNA 35 years ago, no effective treatment exists for the Duchenne Muscular Dystrophy (DMD) patients who have a mutation in this gene. Many treatment options have been considered, investigated preclinically and some clinically, but none have circumvented all barriers and effectively treated the disease without burdening the patients with severe side-effects. However, currently, many novel therapies are in the pipelines of research labs and pharmaceutical companies and many of these have progressed to clinical trials. A brief review of these promising therapies is presented, followed by a description of two novel technologies that when utilized together effectively treat the disease in the mdx mouse model. One novel technology is to generate chimeric cells from the patient's own cells and a normal donor. The other technology is to systemically transplant these cells into the femur via the intraosseous route.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available